Adjuvant Trastuzumab for Breast Cancer Tallal YounisChris Skedgel Commentary 23 December 2012 Pages: 361 - 365
Health Economic and Infectious Disease Modelling Andrea AnonychukMurray Krahn Commentary 23 December 2012 Pages: 367 - 369
Modelling the Epidemiology of Infectious Diseases for Decision Analysis Mark JitMarc Brisson Practical Application 23 December 2012 Pages: 371 - 386
Cost Effectiveness of Treatments for Inflammatory Bowel Disease Keith Bodger Review Article 23 December 2012 Pages: 387 - 401
Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease Nicole MittmannPaul HernandezTobias Welte Original Research Article 23 December 2012 Pages: 403 - 414
Erratum to: Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease Nicole MittmannPaul HernandezTobias Welte Erratum 23 December 2012 Pages: 414 - 414
Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer Peter S. HallClaire HulmeDavid A. Cameron Original Research Article 23 December 2012 Pages: 415 - 432
Is There a Role for Pharmacoeconomics in Developing Countries? Román Pérez VelascoYot Teerawattananon Correspondence 23 December 2012 Pages: 433 - 435
Is There a Role for Pharmacoeconomics in Developing Countries? Jonathan R. Harper Correspondence 23 December 2012 Pages: 435 - 436
The Authors’ Reply Zaheer-Ud-Din BabarShane L. Scahill Correspondence 23 December 2012 Pages: 436 - 437
Rotavirus Vaccine RIX4414 (Rotarix™) Greg L. Plosker Adis Pharmacoeconomic Drug Evaluation 23 December 2012 Pages: 439 - 454